Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Investments (2016 - 2024)

Historic Long-Term Investments for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Q2 2024 value amounting to $42.5 million.

  • Enanta Pharmaceuticals' Long-Term Investments rose 61758.95% to $42.5 million in Q2 2024 from the same period last year, while for Jun 2024 it was $42.5 million, marking a year-over-year increase of 61758.95%. This contributed to the annual value of $29.3 million for FY2022, which is 7298.83% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Long-Term Investments of $42.5 million as of Q2 2024, which was up 61758.95% from $5.9 million recorded in Q2 2023.
  • Enanta Pharmaceuticals' 5-year Long-Term Investments high stood at $115.7 million for Q2 2021, and its period low was $5.9 million during Q2 2023.
  • In the last 5 years, Enanta Pharmaceuticals' Long-Term Investments had a median value of $39.4 million in 2022 and averaged $49.0 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first crashed by 8497.48% in 2023, then soared by 61758.95% in 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Long-Term Investments (Quarter) stood at $18.5 million in 2020, then soared by 380.27% to $88.7 million in 2021, then tumbled by 69.62% to $26.9 million in 2022, then plummeted by 78.01% to $5.9 million in 2023, then soared by 617.59% to $42.5 million in 2024.
  • Its last three reported values are $42.5 million in Q2 2024, $5.9 million for Q2 2023, and $15.0 million during Q1 2023.